Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT02794805 | Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis | completed | Phase 2 | 74 | Meridian Bioscience, Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT04310709 | Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma(RENOBATE) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT03379844 | HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | completed | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 21 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Sep 26, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05517239 | Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment(PEACH) | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 117 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 24, 2022 | clinicaltrials |
| NCT02115373 | c-Met Second-Line Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 66 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02141906 | A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin | completed | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05502458 | Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT02335411 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | completed | Phase 2 | 318 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2022 | clinicaltrials |
| NCT03163992 | Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib | completed | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT00247728 | PI-88 in Hepatocellular Carcinoma After Hepatectomy | completed | Phase 2 | 172 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03409848 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma(INTEGA) | completed | Phase 2 | 97 | AIO-Studien-gGmbHOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 19 | Can-Fite BioPharmaINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | completed | Phase 2 | 48 | Indiana UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02178358 | A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 132 | Eli Lilly and CompanyINDUSTRY | 5 | Feb 25, 2022 | clinicaltrials |
| NCT01962246 | Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction(A-C) | completed | Phase 2 / Phase 3 | 169 | Hebei Medical UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT01900002 | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT00844883 | Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | completed | Phase 2 | 50 | Yale UniversityOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | completed | Phase 2 | 22 | Endeavor HealthOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03410914 | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy(PATCH-DP) | completed | Phase 2 | 52 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT02973516 | Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis | completed | Phase 2 | 41 | GuerbetINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03109886 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tiziana Life Sciences LTDINDUSTRY | 3 | Oct 12, 2021 | clinicaltrials |
| NCT00914355 | Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2) | completed | Phase 2 | 92 | University Health Network, TorontoOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00591123 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | completed | Phase 2 | 38 | Translational Oncology Research InternationalOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01666730 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02089763 | Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Aug 9, 2021 | clinicaltrials |
| NCT00261378 | Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation(PRECISIONV) | completed | Phase 2 | 212 | Boston Scientific CorporationINDUSTRY | 4 | Jul 21, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03245190 | Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 27 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT02859324 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 4 | May 11, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT02564367 | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction(S-1 adjuvant) | completed | Phase 1 / Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT01033240 | CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer | completed | Phase 2 | 172 | Daiichi SankyoINDUSTRY | 4 | Apr 8, 2021 | clinicaltrials |
| NCT01915589 | Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 16 | BayerINDUSTRY | 17 | Apr 8, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2022source: clinicaltrials